Targeting sensitized nerves to treat chronic & debilitating neurogenic disorders

Afferent Pharmaceuticals is a clinical-stage biotechnology company and leader in the development of novel drugs for the treatment of a range of neurogenic disorders. These disorders affect millions of patients who suffer from chronic respiratory and urologic sensory pathologies, as well as chronic pain and cardiovascular disorders, and who have limited, if any, treatment options.

In June 2016, Merck and Afferent signed a definitive agreement under which Merck will acquire Afferent for up to $1.25 billion.

Year Invested: 2009
Location: San Mateo, Calif.

Recent News

June 9, 2016
Merck to Acquire Afferent Pharmaceuticals

May 18, 2016
Afferent Pharmaceuticals Reports Cardiovascular Research Showing P2X3 Antagonism Successfully Reduces Hypertension By Restoring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference

May 16, 2016
Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society (ATS) International Conference

Read More News

Associated Team Members

Kevin Starr